Status:
COMPLETED
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy Subjects
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.
Eligibility Criteria
Inclusion
- Healthy men, aged 18 to 50 years.
Exclusion
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00757341
Start Date
December 1 2008
End Date
December 1 2008
Last Update
April 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tacoma, Washington, United States, 98418